| Released | Contributor | Author | Title | Pages | Price |
|---|
| May 19, 2013 | Market Edge | N/A | Market Edge Equity Research Report | 4 | $10 |
| May 16, 2013 | ValuEngine, Inc. | N/A | ValuEngine Industry Report for Medical-biomed/genetics | 18 | $207 |
| May 15, 2013 | ValuEngine, Inc. | N/A | ValuEngine Detailed Valuation Report for ONCY | 11 | $126.50 |
| May 10, 2013 | S&P Capital IQ Quantitative Report | N/A | Oncolytics Biotech | 5 | $57.50 |
| May 10, 2013 | Pechala's Reports | Frantisek Pechala | ONCOLYTICS BIOTECH INC (ONCY) 12-months forecast | 1 | $15 |
| May 9, 2013 | Zacks Investment Research Inc. | N/A | ONCOLYTICS BIO (ONCY) Zacks Company Snapshot | 1 | $11.50 |
| May 7, 2013 | Edison Investment Research | Mr. Robin Davison, Dr. Mick Cooper | TRANSGENE - KEY TIME APPROACHES | 12 | $10 |
| May 2, 2013 | Zacks Investment Research Inc. | N/A | ONCOLYTICS BIO (ONCY) Zacks Company Snapshot | 1 | $11.50 |
| Apr 17, 2013 | Zacks Investment Research Inc. | N/A | ONCOLYTICS BIO (ONCY) Zacks Company Snapshot | 1 | $11.50 |
| Apr 2, 2013 | Zacks Investment Research Inc. | N/A | ONCOLYTICS BIO (ONCY) Zacks Company Snapshot | 1 | $11.50 |
0.04(1.49%) May 17, 3:59PM EDT